Thomas Klein Selected Research

Dipeptidyl-Peptidase IV Inhibitors

1/2022	Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy-effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker.
1/2021	Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation.
1/2021	Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.
1/2021	Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
1/2021	The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis.
4/2020	SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes.
1/2020	Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy.
1/2018	Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
1/2018	Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
1/2018	The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Klein Research Topics

Disease

23	Type 2 Diabetes Mellitus (MODY) 01/2021 - 04/2013
15	Pain (Aches) 04/2021 - 03/2002
10	Fibrosis (Cirrhosis) 02/2022 - 01/2011
10	Hyperalgesia 05/2020 - 03/2002
9	Stroke (Strokes) 01/2020 - 04/2013
8	Inflammation (Inflammations) 09/2022 - 12/2005
6	Albuminuria 12/2020 - 01/2012
6	Body Weight (Weight, Body) 01/2018 - 01/2012
5	Obesity 01/2021 - 01/2012
5	Hyperglycemia 12/2020 - 03/2015
5	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 01/2012
4	Chronic Renal Insufficiency 12/2020 - 05/2016
4	Hypertension (High Blood Pressure) 01/2019 - 07/2007
3	Ischemia 09/2022 - 07/2013
3	COVID-19 01/2022 - 01/2021
3	Neoplasms (Cancer) 01/2021 - 01/2004
3	Hypertrophy 12/2020 - 01/2017
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2017 - 09/2012
2	Fabry Disease (Fabry's Disease) 01/2022 - 01/2018
2	Heart Arrest (Cardiac Arrest) 01/2022 - 01/2021
2	Cardiogenic Shock 01/2021 - 01/2020
2	Weight Loss (Weight Reduction) 01/2021 - 10/2014
2	Parkinson Disease (Parkinson's Disease) 01/2020 - 01/2019
2	Myocardial Infarction 01/2020 - 07/2007
2	Postoperative Pain 01/2019 - 01/2008
2	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 11/2002
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 12/2005
2	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2018 - 01/2016
2	Neuralgia (Stump Neuralgia) 06/2018 - 01/2008
2	Insulin Resistance 02/2016 - 01/2012
2	Cicatrix (Scar) 06/2015 - 04/2014
2	Alcoholic Fatty Liver 09/2014 - 07/2010
2	Ventricular Tachycardia 04/2014 - 05/2013
2	Infarction (Infarctions) 07/2013 - 12/2008
2	Cardiomyopathies (Cardiomyopathy) 05/2013 - 01/2011
2	Carcinoma (Carcinomatosis) 12/2008 - 10/2003
1	Acute Kidney Injury (Acute Renal Failure) 09/2022
1	Hemorrhage 01/2022
1	Amniotic Fluid Embolism 01/2022
1	Small Fiber Neuropathy 01/2021
1	Nephritis 01/2021

Drug/Important Bio-Agent (IBA)

38	LinagliptinIBA 01/2021 - 01/2011
28	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2022 - 01/2011
16	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2012
15	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 01/2011
8	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2021 - 09/2012
8	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 01/2021 - 09/2014
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2006
5	empagliflozinIBA 09/2022 - 01/2014
5	Telmisartan (Micardis)FDA Link 02/2022 - 01/2012
5	Capsaicin (Zostrix)FDA Link 06/2018 - 03/2002
4	Sodium-Glucose Transporter 2 InhibitorsIBA 09/2022 - 02/2016
4	Pharmaceutical PreparationsIBA 01/2021 - 01/2008
4	Sitagliptin Phosphate (Januvia)FDA Link 08/2020 - 01/2011
3	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 09/2014
3	CreatinineIBA 01/2021 - 01/2019
3	Peptides (Polypeptides)IBA 01/2021 - 11/2002
3	Hypoglycemic Agents (Hypoglycemics)IBA 12/2020 - 09/2014
3	SodiumIBA 12/2020 - 01/2014
3	Insulin (Novolin)FDA Link 12/2020 - 01/2014
3	Angiotensin Receptor AntagonistsIBA 01/2020 - 01/2012
3	Messenger RNA (mRNA)IBA 01/2018 - 01/2011
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2018 - 05/2015
3	Liraglutide FDA Link 01/2017 - 10/2014
3	Neuroprotective AgentsIBA 01/2016 - 09/2014
3	A-factor (Streptomyces)IBA 03/2007 - 03/2002
2	EnzymesIBA 01/2022 - 12/2008
2	Vasopressins (Vasopressin)IBA 01/2021 - 01/2020
2	AlbuminsIBA 01/2021 - 12/2020
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2021 - 01/2020
2	nephrinIBA 12/2020 - 10/2014
2	LeptinIBA 12/2020 - 01/2014
2	alogliptinIBA 08/2020 - 01/2011
2	AntioxidantsIBA 01/2019 - 01/2018
2	glimepiride (Amarel)FDA LinkGeneric 01/2019 - 04/2013
2	Blood Glucose (Blood Sugar)IBA 01/2018 - 10/2017
2	Glucagon-Like Peptide ReceptorsIBA 01/2018 - 05/2015
2	CatalaseIBA 01/2018 - 01/2016
2	IronIBA 01/2017 - 03/2015
2	Retinaldehyde (Retinal)IBA 01/2016 - 07/2012
2	IncretinsIBA 03/2015 - 10/2014
2	Exenatide (Byetta)FDA Link 04/2014 - 01/2012
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2012 - 07/2007
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2008 - 02/2007
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2004 - 10/2003
1	CanagliflozinIBA 09/2022
1	GalactosidasesIBA 01/2022
1	Dacarbazine (DIC)FDA LinkGeneric 01/2022
1	Angiotensin-Converting Enzyme 2IBA 01/2022
1	antiglomerular basement membrane antibodyIBA 01/2021
1	fibroblast activation protein alphaIBA 01/2021

Therapy/Procedure

14	Therapeutics 01/2021 - 01/2004
4	Electrodes (Electrode) 01/2013 - 04/2007
3	Glycemic Control 01/2021 - 01/2016
3	Denervation 01/2021 - 06/2015
2	Extracorporeal Membrane Oxygenation 01/2022 - 01/2021
2	Cardiopulmonary Resuscitation (CPR) 01/2022 - 01/2021
2	Injections 04/2021 - 02/2014
2	Nerve Block (Nerve Blocks) 06/2018 - 09/2015
1	Ligation 01/2021